By Francis Diaz
I recently took a closer look at the new proposed Device Tax, which is part of the Patient Protection and Affordable Care Act, the major healthcare reform legislation signed into law by President Barack Obama. I was tasked with writing up a explanation of the issues so that all of our employees could have a basic understanding.
The landmark healthcare reform law promises to expand coverage to millions of uncovered Americans as well as address the swelling costs of medical care. Several provisions in the law were drafted to help fund this historic undertaking — not the least of which is a 2.3 percent excise tax on medical device manufacturers. The intent of the provision is to raise $20 billion in tax revenues over the course of 10 years and takes effect on the sale of medical devices after December 31, 2012.
With the Rise of AI, What IP Disputes in Healthcare Are Likely to Emerge?
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
While medical device industry advocates generally support many aspects of the new healthcare law, introduction of this new excise tax has been met with consternation. The tax is levied on the manufacturer’s (or importer’s) gross sales price of the finished good, as opposed to net receipts or income. While the tax is significant and carries consequences that affect all industry members, smaller, mid-sized and/or startup medical device firms operating on thin margins are particularly vulnerable. They argue that the imposing the tax threatens to subdue innovation, stifle the flow of investment capital and jeopardize jobs.
In anticipation of the enforcement date of the excise tax and despite the lack of specific guidance from the IRS and the Treasury Dept., companies have begun to identify their exposure and to review options that may mitigate the consequences. For example, can changes be made to a device design to reduce its exposure to a potential tax penalty? Are there costs in the manufacturing process that can be reduced, in order to accommodate the impact of the tax? Successfully navigating these issues begins with a solid understanding of the scope, applicability and limitations of the excise tax. While further legislative and regulatory developments are sure to follow, experts surmise that the key aspects of the tax will remain intact until 2013, when it will take effect. In a future post, I’ll explain a little more about who is responsible for the tax and what qualifies as taxable. What could qualify may surprise you.
Francis Diaz is a research and product strategist for Ximedica. He uses his expertise to deliver qualitative insights and quantitative research to formulate and inform product design opportunities. Francis graduated with an MBA from the Carroll School of Management at Boston College.
(Please note, none of what is included here should in any way be construed as legal advice. Please consult an attorney if you have questions about the legal implications of this topic.)
A Personalized Approach to Medication Nonadherence
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.
The Massachusetts Medical Devices Journal is the online journal of the medical devices industry in the Commonwealth and New England, providing day-to-day coverage of the devices that save lives, the people behind them, and the burgeoning trends and developments within the industry.
